This site is intended for UK healthcare professionals only

NEWS

 

Keep up to date with the latest news on bladder health, management and treatment.

Have you got a story to share? Email the team today.

Study validates new therapy for aggressive bladder cancer
16 February 2022
Yale Cancer Center study validates new therapy for aggressive bladder cancer

Findings from a new study led by Yale Cancer Center researchers show enfortumab vedotin is effective in patients with an form of aggressive bladder cancer (muscle-invasive bladder cancer or MIBC) not eligible for cisplatin chemotherapy.

The data is from Cohort H of the Phase 1/b2 EV-103 clinical trial being presented at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO GU) on February 18, 2022.

“Our findings showed more than one-third of patients displayed no evidence of cancer when their bladder was removed after receiving enfortumab vedotin prior to surgery. The results are significant and so encouraging as survival rates are poor for muscle-invasive bladder cancer.”

Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and Urology and Co-Director of the Cancer Signaling Research Program at Yale Cancer Center, and principal investigator for the study.

MIBC is a type of aggressive bladder cancer where the tumor has spread into the muscle of the bladder wall and more likely to spread to other parts of the body. 25% of bladder cancers are diagnosed as MIBC. Treatment for MIBC typically combines cisplatin-based chemotherapy with surgery.

In this trial, researchers enrolled patients diagnosed with MIBC, ineligible for cisplatin-based chemotherapy, but eligible for surgical treatment. Patients received three cycles of neoadjuvant (prior to surgery) enfortumab vedotin, an antibody-drug, on days one and eight of every three-week cycle. Results from the preliminary analysis of 22 patients showed 36.4 percent had a pathologic complete response, the primary endpoint, displaying no signs of cancer upon microscopic examination of tissue cells removed during surgery. Half of the patients had a pathological downstaging, or reduction in tumor size. All patients underwent surgery, and there were no surgeries delayed due to treatment from enfortumab vedotin.

Petrylak added, “We look forward to phase 3 studies to further evaluate the effectiveness of enfortumab vedotin.”

Funding for this study was provided by Astellas, a multinational pharmaceutical company, and Seagen, an American biotechnology company.

Read more news from The Bladder Interest Group now.

Latest News

Luja™ shows significant improvement in bladder emptying

Study results show that Coloplast’s new intermittent male catheter with 80+ micro-holes, Luja, achieved complete bladder emptying in one free flow* in 90% of catheterisations. Coloplast has finalised its first pivotal clinical study on Luja, a new intermittent male...

Artificial Intelligence used in bladder cancer treatment assessment

A computerised artificial intelligence (AI)-based decision support system (CDSS-T) enhanced the performance of clinicians when assessing patients’ response to chemotherapy prior to radical cystectomy, according to results from a small multi-institutional observer...

New treatment for urothelial cancer approved by NICE

Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new treatment for urothelial cancer – avelumab – following its recommendation for routine NHS funding in final draft guidance published NICE. The recommendation for this...